Guardant Health, Inc. GH
154.78 USD -0.57 (-0.37%)
At closeNov 12, 2026, 4:35 AM EST
154.01 -0.77 -0.50%
Pre-market · Nov 12, 4:35 AM ET
153.41 Day range 163.39
74.55 52-week range 191.05
- YTD
- +51.54%
- 1 year
- +58.41%
News
businesswire.com Guardant Health Prices $500 Million Convertible Senior Notes Offering PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of its offering of $500 million…
businesswire.com Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032 PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced its intention to offer $500.0 million…
businesswire.com Guardant Health Introduces New Epigenomic Applications Providing Deeper Insights for Treatment Selection with Guardant360® Liquid PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new applications for Guardant360® Liquid designed to help oncologists…
businesswire.com PRECISION Study Published in ESMO Open Highlights Utility of Guardant360® Liquid and Guardant Reveal® to Assess Recurrence Risk After Surgery for Colorectal Cancer Metastases PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that ESMO Open has published results from PRECISION, a prospective…
benzinga.com Piper Sandler Maintains Overweight on Guardant Health, Lowers Price Target to $190 Piper Sandler analyst David Westenberg maintains Guardant Health (NASDAQ:GH) with a Overweight and lowers the price target from $193 to $190.
businesswire.com Guardant Health to Participate in Upcoming Investor Conferences PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor…
marketbeat.com What Guardant Health (GH) Said on Its Q3 Earnings Call Guardant Health NASDAQ: GH raised its full-year 2026 revenue forecast after third-quarter sales increased 36%, driven by growth in its oncology testing business and demand for its Shield blood-based…
zacks.com Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates Guardant Health (GH) came out with a quarterly loss of $0.29 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.39 per share a year ago.
zacks.com Guardant Health (GH) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates The headline numbers for Guardant Health (GH) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall…
benzinga.com Guardant Health Q3 2026 Earnings Call Transcript Guardant Health (NASDAQ:GH) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com Guardant Health Raises FY2026 Sales Guidance from $1.340B-$1.360B to $1.360B-$1.370B vs $1.357B Est Guardant Health (NASDAQ:GH) raises FY2026 sales outlook from $1.340 billion-$1.360 billion to $1.360 billion-$1.370 billion vs $1.357 billion estimate.
benzinga.com Guardant Health Q3 Adj. EPS $(0.29) Beats $(0.32) Estimate, Sales $360.975M Beat $350.358M Estimate Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.32) by 9.38 percent. This is a 25.64 percent increase over losses of…
businesswire.com Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2026. Third…
benzinga.com TwinStrand Biosciences Announces Confirmation Of U.S. Patent And Trademark Office Regarding Patentability Of All 23 Claims Of U.S. Patent Against Guardant Health TwinStrand Biosciences (TwinStrand), the pioneer in Duplex Sequencing technology, today announced that the U.S. Patent and Trademark Office (USPTO) has confirmed the patentability of all 23 claims of…- benzinga.com BTIG Maintains Buy on Guardant Health, Raises Price Target to $210 BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $195 to $210.
benzinga.com This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Analysts initiated coverage: VSE Sector Weight; Guardant, Quantum, Benitec and Diodes rated Buy/Overweight/Outperform with targets up to $200.
benzinga.com Roth Capital Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $200 Roth Capital analyst Max Masucci initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $200.
benzinga.com TwinStrand Biosciences Announces U.S. Patent And Trademark Office's Patent Trial And Appeal Board Rejects Guardant Health's Challenge To Core Patent Underlying Duplex Sequencing TwinStrand Biosciences (TwinStrand), the pioneer in Duplex Sequencing® technology, today announced that the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has again rejected…- benzinga.com Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $200 Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $185 to $200.